

Table S1. Number of subjects in each lipid lowering regimen, the mean (standard deviation) LDL-C achieved in mg/dL, the rate of subjects achieving the LDL-C goals of their respective years and the rate of subjects achieving LDL-C <55mg/dl on that regimen.

Medication	Dose	Nr (%)	Mean LDL-C (SD)	% at LDL-C goal	% at LDL-C <55mg/dl
None	N/A	159 (15.9%)	107.7 (48.2)	35/159 (22.0%)	12/151 (7.9%)
Pravastatin	40mg	11 (1.1%)	92.4 (16.7)	1/11 (9.1%)	0/11 (0.0%)
Pravastatin	20mg	1 (0.1%)	103.0 (NA)	0/1 (0.0%)	0/1 (0.0%)
Simvastatin	10mg	3 (0.3%)	104.3 (28.0)	0/3 (0.0%)	0/3 (0.0%)
Simvastatin	20mg	34 (3.4%)	94.9 (46.8)	9/34 (26.5%)	5/34 (14.7%)
Simvastatin	40mg	14 (1.4%)	85 (32.2)	3/14 (21.4%)	3/14 (21.4%)
Atorvastatin	≤10mg	66 (6.6%)	93.1 (31.2)	11/66 (16.7%)	2/66 (3.0%)
Atorvastatin	20mg	150 (15.0%)	89.9 (30.6)	31/150 (20.7%)	6/149 (4.0%)
Atorvastatin	40mg	137 (13.7%)	84.1 (26.3)	43/139 (30.9%)	13/139 (9.4%)
Rosuvastatin	5mg	24 (2.4%)	96.1 (33.4)	6/24 (25.0%)	1/24 (4.2%)
Rosuvastatin	10mg	67 (6.7%)	90.1 (28.1)	13/67 (19.4%)	4/67 (6.0%)
Rosuvastatin	20mg	99 (9.9%)	79.2 (23.9)	28/99 (28.3%)	12/99 (12.1%)
Rosuvastatin	40mg	15 (1.5%)	86.1 (35.4)	4/15 (26.7%)	2/15 (13.3%)
Pitavastatin	1mg	5 (0.5%)	97.2 (57.5)	1/5 (20.0%)	1/5 (20.0%)
Pitavastatin	2mg	11 (1.1%)	96.6 (27.4)	2/11 (18.2%)	2/11 (18.2%)
Pitavastatin	4mg	10 (1.0%)	93.5 (39.2)	1/10 (10.0%)	0/10 (0.0%)
Simvastatin + Ezetimibe	10mg/10mg	4 (0.4%)	98.2 (57.7)	1/5 (20.0%)	1/4 (25.0%)
Simvastatin + Ezetimibe	20mg/10mg	22 (2.2%)	45.2 (11.6)	5/22 (22.7%)	4/22 (18.2%)
Simvastatin + Ezetimibe	40mg/10mg	36 (3.6%)	47.5 (11.9)	8/36 (22.2%)	4/35 (11.4%)
Atorvastatin + Ezetimibe	10mg/10mg	5 (0.5%)	38.6 (6.1)	1/5 (20.0%)	2/5 (40.0%)
Atorvastatin + Ezetimibe	20mg/10mg	33 (3.3%)	76.7 (28.0)	10/33 (30.3%)	6/33 (18.2%)
Atorvastatin + Ezetimibe	40mg/10mg	25 (2.5%)	67.4 (30.0)	11/24 (45.8%)	11/24 (45.8%)
Rosuvastatin + Ezetimibe	5mg/10mg	3 (0.3%)	86.5 (29.0)	0/3 (0.0%)	0/2 (0.0%)
Rosuvastatin + Ezetimibe	10mg/10mg	9 (0.9%)	80.8 (25.8)	2/9 (22.2%)	2/9 (22.2%)
Rosuvastatin + Ezetimibe	20mg/10mg	27 (2.4%)	78.5 (37.2)	7/26 (26.9%)	6/25 (24.0%)
Rosuvastatin + Ezetimibe	40mg/10mg	12 (1.2%)	64.9 (44.0)	7/11 (63.6%)	7/12 (58.3%)
Evolocumab	140mg	1 (0.1%)	53.0 (NA)	1/1 (100.0%)	1/1 (100.0%)
Alirocumab	150mg	1 (0.1%)	43.0 (NA)	1/1 (100.0%)	1/1 (100.0%)
Pravastatin + Ezetimibe	40mg/10mg	1 (0.1%)	64.0 (NA)	0/1 (0.0%)	0/1 (0.0%)
Pravastatin + Fenofibrate	40/145mg	6 (0.6%)	83.4 (12.0)	0/6 (0.0%)	0/6 (0.0%)

Pitavastatin + Ezetimibe	4mg/10mg	1 (0.1%)	85.0 (NA)	0/1 (0.0%)	0/1 (0.0%)
Simvastatin + Fenofibrate	40mg/145mg	3 (0.3%)	94.3 (29.7)	1/3 (33.3%)	0/3 (0.0%)
Atorvastatin + Fenofibrate	20mg + 145mg	2 (0.2%)	78.5 (54.4)	1/2 (50.0%)	1/2 (50.0%)
Rosuvastatin + Fenofibrate	40mg/145mg	1 (0.1%)	72.0 (NA)	0/1 (0.0%)	0/1 (0.0%)
Evolocumab + atorvastatin + Ezetimibe	420mg + 40mg + 10mg	1 (0.1%)	23.0 (NA)	1/1 (100.0%)	1/1 (100.0%)
Fenofibrate	145mg	2 (0.2%)	114.5 (38.9)	0/2 (0.0%)	0/2 (0.0%)